en · de · es · pt
semaglutide-notes.peptides6088.com › Blog › Background And Molecular Profile — Evidence Review

Background And Molecular Profile — Evidence Review

By Editorial Desk · published 2025-11-23 · last reviewed 2026-01-09 · Blog

The short version of receptor agonist fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-01-09 and is reviewed periodically as new material appears.

Background and Molecular Profile

Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.

The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.

Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.

结构特征与受体作用机制

序列层面的改动同时解决了两个问题,即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟,主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库,使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发,属于该类药物化学改造的典型范式。

Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物,其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代,使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸,进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链,该侧链赋予分子与血浆白蛋白结合的能力。

Semaglutide at a glance

PropertyValueNotes
Molecular formula (free base)C187H291N45O59Approximate; salt and hydrate forms differ
Molecular weight~4113.6 DaVaries with counterion and hydration
AppearanceWhite to off-white powderLyophilized research material
Solubility classFreely soluble in waterAs formulated; native peptide less stable near neutral pH
Typical storage2 to 8 degrees CelsiusProtect from light; avoid repeated freeze-thaw

Semaglutide Structure and Receptor Mechanism

Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.

Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.

Related pages on this site

Handling, Storage, And Analytical Checks

Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.

Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.

Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.

Background and Drug Class

Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.

Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.

Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.

Background and Molecular Design

Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.

The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.

Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.

Notes from published material

Asim K. Duttaroy is an Indian-born American medical scientist who, since 2001, has worked as a Professor at the Faculty of Medicine, University of Oslo, Norway. He was born in Gopinagar (Gangnapur), Nadia district, West Bengal, India. Duttaroy is the author of over 535 research papers (h-index 69, i-10 index 242) and book chapters, has authored or edited several books, and holds several international patents. His research contributions have led to several industrial developments worldwide, such as Provexis. Duttaroy, while he worked as Professor (1990-2001) at the Rowett Research Institute at the University of Aberdeen, Scotland, United Kingdom, discovered that an extract from tomato had a positive effect in the prevention of blood platelet aggregation. Hyperactive platelets are important mediators of atherogenesis. In addition to their roles in thrombosis, antiplatelet drugs are not suitable for use where the risk of a cardiovascular event is relatively low. Therefore, it is essential to find alternative, safe antiplatelet inhibitors for the vulnerable population with hyperactive platelets in order to reduce the risk of cardiovascular disease. Potent antiplatelet factors were identified in water-soluble tomato extract (Fruitflow®), significantly inhibiting platelet aggregation. It became the first product in Europe to receive an approved health claim under Article 13(5) of the European Health Claims Regulation 1924/2006 and is now commercially available in over 75 countries.

== Awards and honours == 2007: Foreign associate of the National Academy of Sciences of the United States 2007: Robert Koch Gold Medal 1998: Fellow of the Academy of Medical Sciences (FMedSci). 1973: Elected Fellow of the Royal Society

A composite mythological being with the body of a lion and the head of a human is present in the traditions, mythology and art of South and Southeast Asia. Variously known as puruṣamr̥ga (Sanskrit, "human-animal"), purushamirugam (Tamil, "human-animal"), naravirala (Sanskrit, "human-cat") in India, or as nara-simha (Sanskrit, "human-lion") in Sri Lanka, manussiha or manutthiha (Pali, "human-lion") in Myanmar, and norasingha (from Pali, "human-lion", a variation of the Sanskrit "nara-simha") or thep norasingha ("man-lion deity"), or nora nair in Thailand. Although, just like the "nara-simha", she/he has a head of a lion and the body of a human. In contrast to the sphinxes in Egypt, Mesopotamia, and Greece, of which the traditions largely have been lost due to the discontinuity of the civilization, the traditions related to the "Asian sphinxes" are very much alive today. The earliest artistic depictions of "sphinxes" from the South Asian subcontinent are to some extent influenced by Hellenistic art and writings. These hail from the period when Buddhist art underwent a phase of Hellenistic influence. Numerous sphinxes can be seen on the gateways of Bharhut stupa, dating to the 1st century B.C. In South India, the "sphinx" is known as puruṣamr̥ga (Sanskrit) or purushamirugam (Tamil), meaning "human-animal". It is found depicted in sculptural art in temples and palaces where it serves an apotropaic purpose, just as the "sphinxes" in other parts of the ancient world.

ISBN 0-921991-50-9. Spaeter, Helmuth (1990). Panzerkorps Grossdeutschland: A Pictorial History. Atglen, Pennsylvania: Schiffer Books. ISBN 0-88740-245-3. Ziemke, Earl F. (2002). Stalingrad to Berlin: The German Defeat in the East. Washington, D.C.: Center of Military History. ISBN 978-1-78039-287-5.

== Contraindications == Doxycycline is contraindicated (should not be used) in patients with severe liver disease or those taking isotretinoin or other retinoids, as both tetracyclines and retinoids can cause intracranial hypertension (increased pressure around the brain) in rare cases.

Sources: en.wikipedia.org

Background from the literature

search engines (such as Google Search) targeting online advertisements recommendation systems (offered by Netflix, YouTube or Amazon) driving internet traffic targeted advertising (AdSense, Facebook) virtual assistants (such as Siri or Alexa) autonomous vehicles (including drones, ADAS and self-driving cars) automatic language translation (Microsoft Translator, Google Translate) facial recognition (Apple's FaceID or Facebook's DeepFace and Google's FaceNet) image labelling (used by Facebook, Apple's Photos and TikTok).

In addition, this allowed Germany to gain control of Czech armament (particularly, the Škoda Works), and get rid of the threat of the Czech army and airfields, which were easily in range of Germany. On 8 March 1939, Hitler met with Wilhelm Keppler, the NSDAP's economic expert, where he spoke about his wish to occupy Czecho-Slovakia for economic reasons, saying that Germany needed its raw materials and industries. Hitler totally ignored the agreements of the Munich Agreement and scheduled a German invasion of Bohemia and Moravia for the morning of 15 March. In the interim, he negotiated with the Slovak People's Party and with Hungary to prepare the dismemberment of the republic before the invasion. On 13 March, he invited Tiso to Berlin and on 14 March, the Slovak Diet convened and unanimously declared Slovak independence. Carpatho-Ukraine also declared independence but Hungarian troops occupied and annexed it on 15 March and a small part of eastern Slovakia as well on 23 March.

mTOR Complex 2 (mTORC2) is composed of mTOR, rapamycin-insensitive companion of mTOR (RICTOR), MLST8, and mammalian stress-activated protein kinase interacting protein 1 (mSIN1). mTORC2 has been shown to function as an important regulator of the actin cytoskeleton through its stimulation of F-actin stress fibers, paxillin, RhoA, Rac1, Cdc42, and protein kinase C α (PKCα). mTORC2 also phosphorylates the serine/threonine protein kinase Akt/PKB on serine residue Ser473, thus affecting metabolism and survival. Phosphorylation of Akt's serine residue Ser473 by mTORC2 stimulates Akt phosphorylation on threonine residue Thr308 by PDK1 and leads to full Akt activation. In addition, mTORC2 exhibits tyrosine protein kinase activity and phosphorylates the insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (InsR) on the tyrosine residues Tyr1131/1136 and Tyr1146/1151, respectively, leading to full activation of IGF-IR and InsR.

== Leisure time and unpaid work == In 2010, women in France spent an average of 3 hours and 46 minutes per day on leisure activities, compared to 4 hours and 24 minutes for men. This difference is primarily attributed to disparities in time spent on activities such as gaming, internet use, and sports. According to sociologist Sibylle Gollac (2020), in households with children, men worked an average of 51 hours per week, with two-thirds of that time being paid work. Women worked an average of 54 hours per week, with two-thirds of that time consisting of unpaid work.

A metatarsophalangeal joint sprain is an injury to the connective tissue between the foot and a toe (at a metatarsophalangeal joint, one of the joints in the ball of the foot). When the big toe is involved, it is known as "turf toe".

Sources: en.wikipedia.org

Reference notes

Silent strokes typically cause lesions which are detected via the use of neuroimaging such as fMRI. The risk of silent stroke increases with age but may also affect younger adults. Women appear to be at increased risk for silent stroke, with hypertension and current cigarette smoking being predisposing factors.

Tea was consumed as a recreational and social beverage during the Tang dynasty, and Chinese tea culture-inspired ceremonial drinking spread to other Sinospheric countries such as Japan (where it is known as chado), Korea (known as darye) and Vietnam (typically as part of a wedding ritual). Tea drinking also spread into Inner Asia and South Asia via the Silk Road and the Tea Horse Road, particularly during the expansion of the Mongols, for whom the salted milk tea (süütei tsai) has remained part of the staple diet. Outside of the Far East, Portuguese priests and merchants introduced tea drinking to Europe during the 16th century. During the 17th century, drinking tea became fashionable in Western Europe as part of the rise of Chinoiserie influence, especially among the British, who had such a high import demand of tea that they later started to cultivate tea on a large scale in colonial India and Ceylon, where tea had previously been used only as a herbal medicine.

== History == The a2 Milk Company is the successor of A2 Corporation Limited, a New Zealand company founded in 2000 by Dr Corran McLachlan, who was researching health effects of A1 beta-casein, and Howard Paterson, who was one of New Zealand's richest men, a significant dairy farmer, and a stakeholder in Fonterra, a dairy cooperative. The company commercialised a genetic test to determine whether a cow will produce milk without the A1 protein, and to market A1 protein-free milk. Initially, A2 Corporation focused on dairy farm breeding programmes to develop herds that would produce only A1 protein-free milk. However the launch of A1 protein-free milk was delayed by opposition from Fonterra, which had protected contracts under New Zealand law with about 98% of New Zealand dairy farms. Seeking leverage in the battle with Fonterra over access to farmers, and over patent rights, Paterson led the company into litigation against Fonterra, asking the New Zealand High Court to order Fonterra to put health warnings on its conventional milk concerning risks of type 1 diabetes, heart disease, autism and schizophrenia due to the presence of A1 beta-casein, and to force Fonterra to publicly disclose all the information it had about the links between A1 beta-casein and health risks. The litigation threatened New Zealand's economy and international reputation as at the time Fonterra was responsible for 20% of New Zealand's exports.

Members of the Nashashibi family began to be targeted, as well as the Jewish community and British administrators. Raghib Nashashibi was forced to flee to Egypt after several assassination attempts on him, which were ordered by Amin al-Husayni.

Dean Hamer (; born May 29, 1951) is an American geneticist, author, and filmmaker. He is known for his research on the role of genetics in sexual orientation and for a series of popular books and films that have changed scientific and public understandings and perceptions of human sexuality and gender.

Sources: en.wikipedia.org

Frequently asked questions

What is the relationship between semaglutide and native GLP-1?

It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.

Does the oral form work the same way as the injectable form?

Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.

Is the peptide naturally present in the human body?

No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.

Semaglutide 与天然 GLP-1 的主要差别是什么?

差别集中在三处:第 8 位残基被非天然氨基酸取代,第 34 位换成精氨酸,第 26 位增加一条脂肪酸侧链。前两处改动降低酶解速率,侧链则通过白蛋白结合延长循环时间。综合结果是半衰期从约两分钟延长到约一周。

Network